A Beta-only IL-2 ImmunoTherapY Study

ClinicalTrials.gov ID: NCT05086692

Public ClinicalTrials.gov record NCT05086692. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 17, 2026, 1:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination With Immune Checkpoint Inhibitor in Patients With Advanced Solid Tumors

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors.

Study identification

NCT ID: NCT05086692
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Medicenna Therapeutics, Inc.; Industry
Enrollment: 160 participants

Conditions and interventions

Conditions

Interventions

MDNA11 Drug
Pembrolizumab (KEYTRUDA®) Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Aug 27, 2021 (Actual)
Primary completion: Nov 30, 2026 (Estimated)
Completion: Dec 30, 2028 (Estimated)
Last update posted: Oct 13, 2026

2021 – 2028

United States locations

U.S. sites: 7
U.S. states: 5
U.S. cities: 7

Facility	City	State	ZIP	Site status
Sharp Memorial Hospital	San Diego	California	92123	Active, not recruiting
UCSF Helen Diller Family Comprehensive Cancer Center	San Francisco	California	94158	Active, not recruiting
Providence Saint John's Health Center	Santa Monica	California	90404	Active, not recruiting
Boca Raton Regional Hospital	Boca Raton	Florida	33486	Active, not recruiting
Emory - Winship Cancer Institute	Atlanta	Georgia	30322	Active, not recruiting
Karmanos Cancer Institute	Detroit	Michigan	48201	Active, not recruiting
MD Anderson Cancer Center	Houston	Texas	77030	Active, not recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 21 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05086692, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 13, 2026 · Synced Oct 17, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT05086692 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →